Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
GAITHERSBURG, Md., Feb. 16, 2021 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced it...
-
GAITHERSBURG, Md., Feb. 15, 2021 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, and SK Bioscience, a...
-
GAITHERSBURG, Maryland, Feb. 04, 2021 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq: NVAX), ein Biotechnologieunternehmen, das Impfstoffe der nächsten Generation für schwere Infektionskrankheiten...
-
Rolling reviews have commenced by FDA, MHRA, EMA and Health Canada GAITHERSBURG, Md., Feb. 04, 2021 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing...
-
GAITHERSBURG, Md., Feb. 03, 2021 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that...
-
GAITHERSBURG, Md., Feb. 02, 2021 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced...
-
GAITHERSBURG, Md., Feb. 01, 2021 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that...
-
First to Demonstrate Clinical Efficacy Against COVID-19 and Both UK and South Africa Variants Strong efficacy in Phase 3 UK trial with over 50% of cases attributable to the now-predominant UK...
-
GAITHERSBURG, Md., Jan. 22, 2021 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today...
-
GAITHERSBURG, Md., Jan. 22, 2021 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today...